Scholars@Duke
construction release_alert
Profile editing will be unavailable for Scholars@Duke profiles from June 11-24, 2026 as manual profile data entry transitions to Elements. More information about the transition.
cancel
Binita Chakraborty

Binita Chakraborty

Research Scientist
Pharmacology & Cancer Biology

Selected Publications

Single-cell transcriptomics reveals immune landscape dynamics in metastatic hormone receptor-positive breast cancer treated with abemaciclib and endocrine therapy.

Journal Article Clin Cancer Res · May 13, 2026 PURPOSE: In advanced estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, the combination of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) with endocrine therapy (ET) is the standard of care for ... Full text Link to item Cite

The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.

Journal Article Mol Cancer Ther · April 2, 2026 Endocrine therapy has proven to be beneficial for patients with estrogen receptor (ER)-positive, HER2-negative (ER+/HER2-) breast cancer; however, de novo or acquired resistance remains a major clinical challenge. Upon progression, many of the cancers cont ... Full text Link to item Cite

Supplementary Table S5 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <p>Supplementary Table S5 shows Cell proliferation IC50 and maximum inhibition (Emax) in parental and ERY537S (heterozygous) after different ER ligands treatment.</p> ... Full text Cite

Data from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <div>Abstract<p>Endocrine therapy has proven to be beneficial for patients with estrogen receptor (ER)–positive, HER2-negative (ER<sup>+</sup>/HER2<sup>−</sup>) breast cancer; however, <i>de novo</i> ... Full text Cite

Supplementary Figure S2 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <p>Supplementary Figure S2 shows ZN-c5 demonstrates minor agonist effect on uterine tissue A. Uterine wet weight change in juvenile rats treated with different doses of ZN-c5. B. H&E staining on uterine tissues after ZN-c5 treatment. Imag ... Full text Cite

Supplementary Figure S5 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <p>Supplementary Figure S5 shows ZN-c5 activity in ERY537S tumors. A. Key ER downstream targets expression by qPCR in WT or ERY537S heterozygous cells. B. ER downstream target GREB expression by qPCR in WT or ERY537S heterozygous cells after ... Full text Cite

Supplementary Figure S1 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <p>Supplementary Figure S1 shows ZN-c5 is a novel SERD that inhibits growth of ER + tumors in vitro and in vivo A. ERα degradation curve after ZN-c5 treatment and DC50 (concentration at 50% degradation) determination for Figure 1B top; B. Top ... Full text Cite

Supplementary Figure S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <p>Supplementary Figure S4 shows Combination of ZN-c5 and palbociclib further arrests the cells at G1 phase A. Relative ER level to DMSO after normalized to β-actin control for Figure 4B. B. MCF-7 cells were treated with 500nM of palbociclib ... Full text Cite

Supplementary Table S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <p>Supplementary Table S3 shows The effect of ZN-c5 and tamoxifen on E2-induced genes</p> ... Full text Cite

Supplementary Table S2 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <p>Supplementary Table S2 shows ZN-c5 human nuclear receptor profiling and estrogen receptor binding affinity</p> ... Full text Cite

Supplementary Table S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <p>Supplementary Table S4 shows The effect of ZN-c5 and tamoxifen on E2-suppressed genes</p> ... Full text Cite

Supplementary Figure S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <p>Supplementary Figure S3 demonstrates ZN-c5 protects bone loss in ovariectomized mice A. Progesterone level in serum was measured after Ovariectomy (OVX) or sham surgery to confirm the success of ovariectomy. B and C. BMD in femur and tibia ... Full text Cite

Data from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Other · November 24, 2025 <div>Abstract<p>Triple-negative breast cancers (TNBC) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early-stage localized TNBC, the rate of distant recurrence remains hi ... Full text Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Other · November 24, 2025 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growth.

Journal Article Sci Adv · September 27, 2024 Estrogens regulate eosinophilia in asthma and other inflammatory diseases. Further, peripheral eosinophilia and tumor-associated tissue eosinophilia (TATE) predicts a better response to immune checkpoint blockade (ICB) in breast cancer. However, how and if ... Full text Open Access Link to item Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis

Other · September 16, 2024 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Data from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis

Other · September 16, 2024 <div>Abstract<p>Triple-negative breast cancers (TNBCs) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early stage localized TNBC, the rate of distant recurrence remains h ... Full text Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis

Other · September 16, 2024 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis.

Journal Article Cancer Res · September 1, 2023 UNLABELLED: Triple-negative breast cancers (TNBC) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early-stage localized TNBC, the rate of distant recurrence remains high, and long-term surviv ... Full text Open Access Link to item Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Other · September 1, 2023 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Other · September 1, 2023 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Data from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Other · September 1, 2023 <div>Abstract<p>Triple-negative breast cancers (TNBC) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early-stage localized TNBC, the rate of distant recurrence remains hi ... Full text Cite

WDR5 supports colon cancer cells by promoting methylation of H3K4 and suppressing DNA damage.

Journal Article BMC cancer · June 2018 BackgroundKMT2/MLL proteins are commonly overexpressed or mutated in cancer and have been shown to support cancer maintenance. These proteins are responsible for methylating histone 3 at lysine 4 and promoting transcription and DNA synthesis; howe ... Full text Cite